Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ICLR
ICLR logo

ICLR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy ICON PLC (ICLR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
116.500
1 Day change
3.04%
52 Week Range
211.000
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ICON PLC (ICLR) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is facing significant uncertainties due to accounting investigations and weak financial performance, despite some analysts viewing the current price as undervalued. Given the lack of strong positive catalysts, mixed analyst ratings, and no proprietary trading signals, it is advisable to hold off on buying this stock for now.

Technical Analysis

The MACD is positive at 1.77, indicating a mild bullish trend, but it is contracting. RSI is neutral at 49.239, suggesting no clear momentum. Moving averages are converging, and the stock is trading near its pivot level of 107.843, with support at 101.97 and resistance at 113.717. Overall, the technical indicators do not provide a strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high option volume put-call ratio of 1.88 indicates bearish sentiment among options traders, while the open interest put-call ratio of 0.64 suggests a moderate level of bearish positioning.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
8

Positive Catalysts

  • Some analysts, such as BMO Capital and Jefferies, have upgraded the stock to Buy, citing its undervaluation and the overreaction to accounting concerns. The stock is trading at a multi-decade low valuation, which some view as an attractive entry point.

Neutral/Negative Catalysts

  • The company is under an internal accounting investigation, which has led to significant downgrades and price target reductions from analysts like Barclays, Citi, and Rothschild & Co. Financial performance in Q3 2025 was weak, with a sharp decline in net income (-98.81% YoY) and EPS (-98.73% YoY). There is also no recent news or congress trading data to suggest positive sentiment.

Financial Performance

In Q3 2025, revenue increased slightly by 0.63% YoY to $2.04 billion. However, net income dropped significantly by 98.81% YoY to $2.36 million, and EPS fell by 98.73% to $0.03. Gross margin also declined by 9.08% to 22.32%, indicating worsening profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. While some firms like BMO Capital and Jefferies upgraded the stock to Buy, others like Citi, Barclays, and Rothschild downgraded it due to accounting uncertainties and reduced price targets. Price targets range widely from $75 to $135, reflecting uncertainty in the stock's outlook.

Wall Street analysts forecast ICLR stock price to rise
13 Analyst Rating
Wall Street analysts forecast ICLR stock price to rise
6 Buy
7 Hold
0 Sell
Moderate Buy
Current: 116.500
sliders
Low
172
Averages
202.67
High
222
Current: 116.500
sliders
Low
172
Averages
202.67
High
222
BMO Capital
Sean Dodge
Market Perform
to
Outperform
upgrade
$100 -> $130
AI Analysis
2026-03-26
Reason
BMO Capital
Sean Dodge
Price Target
$100 -> $130
AI Analysis
2026-03-26
upgrade
Market Perform
to
Outperform
Reason
BMO Capital analyst Sean Dodge upgraded Icon to Outperform from Market Perform with a price target of $130, up from $100. The firm's recent analysis indicates continued improvements in Icon's large pharma backdrop. In additions, the shares are trading at a multi-decade low valuation, the analyst tells investors in a research note. BMO believes current share levels overly discount the risks from Icon's accounting review and longer-term AI fears overhanging the space. It sees current levels as an attractive entry point.
Citi
Patrick Donnelly
Neutral
downgrade
$200 -> $120
2026-03-11
Reason
Citi
Patrick Donnelly
Price Target
$200 -> $120
2026-03-11
downgrade
Neutral
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Icon to $120 from $200 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Citi sees room for upside to the Q1 outlooks if biopharma activity continues to improve. The firm named Agilent its top tools pick, Natera its top diagnostics pick, and Charles River its top contract research organization pick.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ICLR
Unlock Now

People Also Watch